Edwards Lifesciences Corporation Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EW

Classificação em ações #478
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Preço da ação
$88.23
Última sincronização: 2026-10-20
Valor de mercado
$50.86B
Variação (1 dia)
1.08%
Variação (1 ano)
16.06%
País
US
Negociar Edwards Lifesciences Corporation (EW)

Categoria

Healthcare
Receita da Edwards Lifesciences Corporation (EW)
Receita em Jun 2026 TTM: $6.51B
De acordo com os últimos relatórios financeiros da Edwards Lifesciences Corporation, a receita atual da empresa (TTM) é $6.51B. Em 2024, a empresa obteve uma receita de $5.44B um aumento em relação a a receita do ano 2023, que foi de $5.01B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Edwards Lifesciences Corporation de 2000 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $6.51B 7.33%
2025 $6.07B 11.55%
2024 $5.44B 8.57%
2023 $5.01B -6.92%
2022 $5.38B 2.86%
2021 $5.23B 19.29%
2020 $4.39B 0.88%
2019 $4.35B 16.79%
2018 $3.72B 8.37%
2017 $3.44B 15.91%
2016 $2.96B 18.85%
2015 $2.49B 7.35%
2014 $2.32B 13.56%
2013 $2.05B 7.68%
2012 $1.90B 13.17%
2011 $1.68B 16.01%
2010 $1.45B 9.51%
2009 $1.32B 6.76%
2008 $1.24B 13.44%
2007 $1.09B 5.22%
2006 $1.04B 3.92%
2005 $997.90M 7.13%
2004 $931.50M 8.25%
2003 $860.50M 22.23%
2002 $704.00M 1.73%
2001 $692.00M -13.93%
2000 $804.00M 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$46.59B 615.34%
US
$35.48B 444.88%
IE
$25.84B 296.74%
US
$21.00B 222.41%
US
- -
DE